Samsung Biologics Wins Lawsuit Against Korea Regulator: Yonhap

Seoul Administrative Court ruled that South Korean financial regulator should cancel disciplinary actions on Samsung Biologics that were imposed for alleged accounting standard violation in 2018, Yonhap News says, citing the court.

• South Korea’s financial regulator in 2018 called for dismissal of company executives and imposed 8b won in fines, saying Samsung Biologics allegedly changed the value of affiliate Samsung Bioepis deliberately
• The decision is in line with Seoul Central District Court’s Feb. ruling for acquittal of Samsung Electronics Executive Chairman Jay. Y Lee on charges of accounting fraud
  • Seoul court ruled that it was not fraudulent accounting, saying ...